Skip to Main Content

Hims & Hers Health, Inc. (NYSE: HIMS) Securities Fraud Investigation

On June 23, 2025, during pre-market hours, the pharmaceutical company Novo Nordisk announced it would no longer provide Hims & Hers with direct access to its FDA-approved weight loss drug Wegovy through NovoCare Pharmacy due to concerns about illegal mass compounding and deceptive marketing by Hims & Hers.  Specifically, Novo Nordisk explained that Hims & Hers allegedly failed to comply with laws prohibiting mass sales of compounded drugs and disseminated “deceptive marketing that put patient safety at risk."  

When the market opened, Hims & Hers stock price opened at $48.16, over 20% less than its closing price of $64.22 on June 20, 2025, and the stock price continued to tumble during intraday trading.      
 

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.  

Complete this form with your transactions in Hims & Hers Health, Inc. securities between May 6, 2025 and June 20, 2025.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Purchase(s)
+ Additional Purchases
Sale(s)
+ Additional Sales
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Hims & Hers Health, Inc. prior to the Class Period?
Are you a current or former employee of Hims & Hers Health, Inc. ?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email
Submit Your Information